Azaindazole Compounds As CCR1 Receptor Antagonists

A method of treating chronic inflammation, allergies, contact dermatitis, psoriasis, rheumatoid arthritis, multiple sclerosis, type 1 diabetes, inflammatory bowel disease, Guillain-Barre syndrome, Crohn's disease, ulcerative colitis, graft versus host disease, Alzheimer's disease, asthma, chronic kidney disease, sepsis, autoimmune myocarditis or systemic lupus erythematosus, comprising administering to a patient a pharmaceutically effective amount of a compound of the formula (I)

• wherein
• W is carbon and Y is nitrogen or, W is nitrogen and Y is carbon;
• Ar1 is carbocycle, heteroaryl or heterocyclyl each optionally substituted by one to three Ra;
• Ar2 is carbocycle, heteroaryl or heterocyclyl, each optionally substituted by one to three Rb;
• R1 is hydrogen, C1-6 alkyl or C1-6 alkoxyC1-6 alkyl;
• R2, R3 are each independently hydrogen, C1-6 alkyl or C1-6 alkenyl, wherein the C1-6 alkyl or alkenyl is optionally partially or fully halogenated or substituted with one to three groups independently selected from cyano, C1-6 alkoxy, hydroxyl, —CO2C1-6 alkyl, —C(O)N(Re)(Rf), —N(Re)(Rf) and heterocyclyl optionally substituted by oxo;
• Ra is C1-6 alkyl, C3-10 cycloalkyl, C1-6 alkoxy, C1-6 alkylthio, C1-6 alkylsulfonyl, C1-6 alkoxycarbonyl, amino, mono-or di-C1-6 alkylamino, C3-6 cycloalkylamino, C1-6 alkylaminocarbonyl, C1-6 acyl, C1-6 acylamino, C1-6 dialkylaminocarbonyl, hydroxyl, halogen, cyano, nitro, oxo, R4—S(O)m—NH—, R4—NH—S(O)m—, aryl or carboxyl;
• Rb is hydroxyl, carboxyl, halogen, —(CH2)n—CN, —(CH2)n—CO2C1-6alkyl, nitro, —SO3H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-10 cycloalkyl, C1-6 alkoxy, C1-6alkylC(O)—, —(CH2)n—NRcRd, R4—S(O)m(CH2)0-1—, R4—S(O)m—NRe—, R4—NRe—S(O)m(CH2)0-1—, —NRf—C(O)—Re, —(CH2)x—C(O)—(CH2)n—NRcRd, heterocyclyl, aryl or heteroaryl, each Rb where possible is optionally halogenated or substituted with 1 to 3 C1-6 alkyl, hydroxyl, C1-6 acyl, C1-6 alkoxycarbonyl, C1-6 alkyl-S(O)m—, aryl or carboxyl;
• each Rc, Rd are independently hydrogen, C1-6 alkyl, C1-6 acyl, C3-10 cycloalkyl, C1-6 alkoxy, hydroxyC1-6 alkyl, cyano-C1-6 alkyl, C1-6 alkylC1-6 alkoxy, C1-6 alkylsulfonyl, C1-6 alkoxycarbonylC0-3alkyl, —(CH2)n—C(O)—NReRf or —(CH2)n—NReRf;
• each Re, Rf are independently hydrogen, C1-6 alkyl, C3-10 cycloalkyl, C1-6 alkoxy, C1-6 alkoxyC1-6alkyl, mono-or diC1-6alkylaminoC1-6alkyl, hydroxyC1-6 alkyl or C1-6 acyl;
• R4 is hydrogen, C1-6 alkyl, C3-6cycloalkyl, heterocyclyl(CH2)0-1, mono-or di-C1-6 alkylamino, mono-or di-1-6alkylamino(CH2)2-3N(Re)-, aryl or heteroaryl each optionally substituted with 1 to 3 C1-6 alkyl, C3-6cycloalkyl, C1-6alkoxy, halogen, hydroxyl, oxo, carboxyl, —C(O)NReRf, amino, mono-or di-C1-6 alkylamino, C1-6 alkoxycarbonyl or C1-6 acylamino;
• each n, x are independently 0-3;
• each m is independently 0-2;
• or a pharmaceutically acceptable salt thereof.